Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

By I. Tannock, R. de Wit, W. Berry, J. Horti, A. Płużańska, K. Chi, S. Oudard, C. Théodore, N. James, I. Turesson and 2 more. New England Journal of Medicine, 2004

5,761 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Urology

View Paper: https://www.semanticscholar.org/paper/d74c743240529a3aa1fa931245db5140385526f4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

Citations in the corpus

Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. (2013, methodology): “With data from the TAX 327 trial indicating that docetaxel may be more effective in patients with no pain at baseline [3,4], the effect on survival related to the delay of chemotherapy in metastatic CRPC patients is unknown.”
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. (2005, background): “These patients should be offered aggressive combined multimodality treatment using hormonal and cytotoxic chemotherapy, particularly in light of recent data suggesting that chemotherapy can modestly, but significantly, prolong survival in patients with hormone refractory disease.(31,32) In a cohort ”
Randomized Phase 3 Trial of Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer and No Prior Chemotherapy (2012, neutral): “Adverse event leading to death* 20 (4) 12 (2) Adverse event of grade 1–4 in ≥15% of patients in either group Fatigue 212 (39) 185 (34) Back pain 173 (32) 173 (32) Arthralgia 154 (28) 129 (24) Nausea 120 (22) 118 (22) Constipation 125 (23) 103 (19) Hot flush 121 (22) 98 (18) Diarrhea 117 (22) 96 (18)”
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. (2007, background): “Docetaxel is now the standard of care across North America for patients with metastatic androgenindependent disease because of a survival advantage observed in two large randomized studies, and many other systemic therapies are currently being tested.(15,16) The hazard ratios reported by Tannock et ”
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “Improved 3 [102]”
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008, background): “The demonstration of a survival benefit in a phase III trial and a confirmatory trial(7) led to the approval of docetaxel in 2004.(6) Since then, clinical trials for patients with castrate metastatic disease are being designed in three contexts: before receiving treatment with docetaxel, with agents”
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. (2008, background): “No survival benefit was detected in trials comparing mitoxantrone plus corticosteroids with corticosteroids alone, although the studies were not powered to detect small differences in survival.1,2 In 2004, reports of the TAX 327 and Southwest Oncology Group 99-16 studies showed significant survival ”